Latest news with #Saluda
Fox News
15-07-2025
- Fox News
Woman dies after falling at least 75 feet while hiking in North Carolina
A woman died over the weekend after falling at least 75 feet from a hiking trail while visiting a waterfall in North Carolina, according to officials. Astrid Angelina Madrid Ticas, 29, was identified as the victim who fell on Sunday around 1:30 p.m. at Big Bradley Falls near Saluda, North Carolina, Polk County officials wrote in a news release Monday. "As a community, Polk County extends its heartfelt condolences to the family and loved ones of Ms. Ticas during this difficult time," the county said. Authorities were called to the Big Bradley Falls Trailhead at Holbert Cove Road in Saluda, with crews from Saluda Fire and Rescue, Mill Spring Fire Department, Polk County Emergency Management and the Polk County Sheriff's Office dispatched to the scene. "Upon arrival, crews discovered that a mid-to late 20-year-old female had fallen an estimated 75 to 100 feet. Unfortunately, she succumbed to her injuries at the scene," the county wrote in an earlier release on Sunday. Rescue personnel worked diligently to recover the victim, the county said, adding that it urges the public to exercise caution while visiting trails and natural areas. It remains unclear how the woman fell. Big Bradley Falls is a 75-foot waterfall located in a small gorge along Cove Creek near Saluda, according to the Blue Ridge Mountain Life website. "Big Bradley Falls is a gorgeous waterfall that is difficult to reach, and somewhat dangerous to even view. The most popular trail to the base of the falls requires a hike down a steep trail, followed by a 20-foot rope descent down a cliff side," the website said. The incident on Sunday comes a week after another victim died at a different waterfall in the state. Yoseph Alabdulwahab, 25, drowned at the base of Steele Creek Falls in Pisgah National Forest, according to Burke County Emergency Services. Steele Creek Falls is about a 75-mile drive from Big Bradley Falls.
Yahoo
15-07-2025
- Yahoo
29-Year-Old Hiker Dies at a North Carolina Waterfall After Falling 75-100 Feet, Second Fall-Related Death in a Week
North Carolina authorities responded to an accident involving a fall from Big Bradley Falls on Sunday, July 13 The victim was identified as Astrid Angelina Madrid Ticas, 29 In another accident on July 6, a climber died in a rappelling incident at Steele Creek Falls in Pisgah National ForestAuthorities confirmed that a hiker fell to her death at a North Carolina waterfall over the weekend. The victim was identified as Astrid Angelina Madrid Ticas, 29, said Polk County in a news release issued on Monday, July 14. According to the county, authorities on Sunday, July 13, received a 911 call at around 1:30 p.m., local time, about an accident involving a fall from Big Bradley Falls in Saluda. 'Saluda Fire and Rescue, Mill Spring Fire Department, Polk County EMS, Polk County Emergency Management and the Polk County Sheriff's Office were dispatched to the scene, located at the Big Bradley Falls Trailhead, 4960 Holbert Cove Rd.,' the news release stated. When emergency responders arrived, they learned that a woman fell about 75 to 100 feet, the county's statement continued, 'Unfortunately, she succumbed to her injuries at the scene,' the county said of Ticas, adding that crews worked diligently to recover her body. 'As a community, Polk County extends its heartfelt condolences to the family and loved ones of Ms. Ticas during this difficult time,' read the statement. No further information was given about the circumstances leading to her fall and death. PEOPLE contacted Polk County's public information officer on Monday. 'We urge the public to exercise caution while visiting local trails and natural areas,' said the county in its news release. Ticas' death marked the second time in a week in which someone died at a North Carolina waterfall. On July 6, a climber died in a rappelling incident at Steele Creek Falls in Pisgah National Forest, located in the western part of the state, according to a news release from Burke County Emergency Services shared with PEOPLE. 'While Emergency Services were enroute, a second call was received by Burke County Emergency Communications advising that the individual had possibly drowned and bystanders at the scene had initiated CPR. Due to the challenging terrain and remote location, technical rescue teams required a significant amount of time to reach the victim safely,' the statement read. 'Despite the bystanders' life-saving efforts, the patient was pronounced deceased after emergency crews made access to the scene an hour later,' it continued. Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. The victim was identified by officials as Yoseph Alabdulwahab, 25, per the Charlotte Observer. 'We express our deepest thoughts and condolences to the victim's family and loved ones during this difficult time,' James Robinson, Burke County Emergency Services director, said in the news release. Read the original article on People
Malaysian Reserve
30-06-2025
- Business
- Malaysian Reserve
Saluda Medical Appoints Barry Regan as Chief Executive Officer
Follows the Addition of Mike Mathias as Chief Commercial Officer in Late 2024 and Jim Erickson as Chief Financial Officer in Late 2023 MINNEAPOLIS, June 30, 2025 /PRNewswire/ — Saluda Medical, Inc., a pioneer in the development and commercialization of a novel neuromodulation platform designed to transform the lives of patients with chronic neurological conditions, today announced the appointment of Barry Regan as President and Chief Executive Officer effective as of July 14, 2025. In his most recent roles, Mr. Regan served as Executive Vice President, Global Operations at Dexcom and Senior Vice President, Global Operations at Wright Medical. 'We are thrilled to welcome Barry to Saluda and are fortunate to augment our leadership team with his extensive experience at a critical juncture,' said Doug Godshall, Chairman of the Board of Directors of Saluda Medical. 'Combined with the recent appointments of Mike Mathias as Chief Commercial Officer and Jim Erickson as Chief Financial Officer, we are confident Saluda has the right team of seasoned and driven leaders in place to fully realize our vision of bringing scientifically-based spinal cord stimulation, and neuromodulation more broadly, into the future with our unparalleled dose-controlled, closed-loop platform. On behalf of the Board, we also extend our gratitude to Jim Schuermann for his contributions to the Company and wish him success in his future endeavors.' Bob Palmisano, Board Member of Saluda Medical and former Chief Executive Officer of Wright Medical added, 'I am excited to work with Barry again following our time together at Wright. Barry's proven track record of driving transformational change to support growth and profitability at large, global healthcare organizations, including at Wright and most recently at Dexcom, will undoubtedly benefit Saluda as the Company continues to scale commercial operations for the Evoke System.' 'I am thrilled to join Saluda as Chief Executive Officer at this exciting time,' said Barry Regan. 'I look forward to working with Mike Mathias, Jim Erickson, Doug, Bob, and the entire team to continue establishing Saluda as a new standard of care in neuromodulation and transforming the lives of patients with chronic neurological conditions.' About Barry ReganMr. Regan brings more than 30 years of operations experience across both the medical device and pharmaceutical industries to his new role as President and CEO of Saluda Medical. Most recently, he served as Executive Vice President, Global Operations at Dexcom, which included responsibility for overseeing the capital investment strategy supporting the scale-up of internal and external supplier manufacturing processes for Dexcom's continuous glucose monitoring (CGM) products. Prior to Dexcom, Mr. Regan held the role of Senior Vice President, Global Operations at Wright Medical, and before that, Senior Vice President, Global Supply Chain at Smith & Nephew. Earlier in his career, Mr. Regan served as Vice President, Manufacturing & General Manager, Puerto Rico at AbbVie, and also held various positions at Abbott of increasing responsibility over a 17-year period. He holds a Bachelor of Technology from the University of Limerick and an MBA from Lake Forest Graduate School of Management. About Saluda MedicalSaluda Medical is a commercial-stage medical device company focused on developing treatments for chronic neurological conditions using its novel neuromodulation platform. The Company's closed-loop, dose-control platform senses and measures neural responses to stimulation and automatically adjusts therapy based on real-time neurophysiological feedback. The Company's first product, the Evoke® System, is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain, and leg pain, and is designed to treat chronic neuropathic pain by providing spinal cord stimulation (SCS) therapy that senses and measures neural activation to optimize therapy and reduce patient and clinician burden. 12-month results from the EVOKE study, the first and only prospective, multi-center, parallel-arm, double-blind, randomized controlled pivotal study with a voluntary crossover arm in SCS, that demonstrated clinically superior pain relief to open-loop therapy, were published in The Lancet Neurology, 24-month results were published in JAMA Neurology, and 36-month data, that demonstrated sustained pain relief, were published in Regional Anesthesia and Pain Medicine. To learn more, including risks and important safety information, visit Saluda and Evoke are registered trademarks owned by Saluda Medical Pty Ltd. Investor Contacts: Brian Johnston or Sam Bentzingerbrian@ sam@
Associated Press
05-02-2025
- Health
- Associated Press
Saluda Medical Announces Presentation of New Clinical Data at the 2025 NANS Annual Meeting
Presentations Included First Human Data on EVA™, Saluda's Automated SCS Programming Platform MINNEAPOLIS, Feb. 5, 2025 /PRNewswire/ -- Saluda Medical, Inc., a pioneer in the development and commercialization of a novel neuromodulation platform designed to transform the lives of patients with chronic neurological conditions, today announced the presentation of new clinical data at the 2025 North American Neuromodulation Society (NANS) Annual Meeting, held from January 30 – February 1, 2025, in Orlando, FL. Data from 11 total abstracts and four oral presentations, two of which received the 'Top Oral Abstract' award, underscore the significance of objective neurophysiological measurements in spinal cord stimulation (SCS) with evoked compound action potential (ECAP) dose-controlled closed-loop therapy, and the potential clinical benefits of Saluda Medical's recently FDA-approved automated patient programming platform, EVA™. Highlights from EVA™ Automated Programming Abstract: 'Novel Automated Platform to Upgrade SCS Programming Experience from Subjective to Objective: Results from a Prospective, Dose-Controlled Closed-loop Clinical Study,' by Ajay Anthony, MD: 94% of all programming sessions using the automated programming platform successfully generated a closed-loop program <13-minute median time to generate each patient-specific automated program ≥90% of patients were satisfied or very satisfied with the automated programming platform experience Highlights from 'Top Oral Abstracts": 'ECAP Study Premiere: Real-World IDE Study Showing Relationship between Physiologic ECAP Biomarkers and Pain Outcomes,' by Jason Pope, MD: The ECAP IDE Study builds on the EVOKE IDE Study and represents the largest SCS study executed in a real-world cohort of 220 patients Real-world data demonstrated profound improvement (≥2 MCIDs) across all pain subgroups in the study including pain associated with Failed Back Surgery Syndrome, Non-Surgical Back Pain, Complex Regional Pain Syndrome, Diabetic Peripheral Neuropathy, and Upper Limb Pain 'Characterizing Spinal Cord Neurophysiology Using ECAP Dose-Controlled Closed-Loop SCS,' by Harold Nijhuis, MD: First SCS study to objectively characterize differences in cervical and thoracic spinal neurophysiology Significantly higher cervical SCS sensitivity may increase the risk of over- and under-stimulation when using open-loop SCS Precise dosing on a pulse-pulse basis using an ECAP dose-controlled closed-loop SCS may be necessary for durable long-term outcomes in the cervical spine 'Saluda is driving a pivotal moment in SCS, where advanced neurophysiological data and automation are redefining the standard of care,' said Jim Schuermann, President and CEO of Saluda Medical. 'We believe the next generation of SCS is here, and it's built on the foundation of objective science, precision, and personalized therapy that will continue to elevate patient care for years to come.' 'What stands out to me about these results is the newfound clarity in understanding the relationship between ECAP biomarkers and pain outcomes,' said Dr. Jason Pope, MD, Founder and CEO of Evolve Restorative Center. 'This real-world data from the largest SCS IDE study gives us confidence that tailored therapy with the Evoke System can significantly improve pain relief across multiple patient etiologies we treat in our practices. This kind of personalized, biomarker-driven therapy is leading to other breakthroughs such as predicting responders and non-responders to therapy and automation of programming to achieve the best relief for our patients.' The recognition of the Evoke® System at the 2025 NANS Annual Meeting highlights Saluda's commitment to advancing the field of neuromodulation through cutting-edge science and innovation. By combining real-world clinical evidence, objective biomarkers, and automation. Saluda is empowering clinicians to deliver more precise, personalized, and effective therapies for patients with chronic pain. These achievements underscore Saluda Medical's leadership in redefining SCS and its unwavering dedication to improving the lives of millions of patients. About Saluda Medical Saluda Medical is a commercial-stage medical device company focused on developing treatments for chronic neurological conditions using its novel neuromodulation platform. The Company's closed-loop, dose-control platform senses and measures neural responses to stimulation and automatically adjusts therapy based on real-time neurophysiological feedback. The Company's first product, the Evoke® System, is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain, and leg pain, and is designed to treat chronic neuropathic pain by providing spinal cord stimulation (SCS) therapy that senses and measures neural activation to optimize therapy and reduce patient and clinician burden. 12-month results from the EVOKE study, the first and only prospective, multi-center, parallel-arm, double-blind, randomized controlled pivotal study with a voluntary crossover arm in SCS, that demonstrated clinically superior pain relief to open-loop therapy, were published in The Lancet Neurology, 24-month results were published in JAMA Neurology, and 36-month data, that demonstrated sustained pain relief, were published in Regional Anesthesia and Pain Medicine. To learn more, including risks and important safety information, visit Investor Contacts:
